Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia-Value for Money Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia-Value for Money Analysis
Authors
Keywords
Hypertriglyceridemia, Icosapent ethyl, Major adverse cardiovascular events, Outcomes research
Journal
AMERICAN JOURNAL OF MEDICINE
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-01-13
DOI
10.1016/j.amjmed.2020.12.023
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction
- (2020) Zanfina Ademi et al. European Journal of Preventive Cardiology
- Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial
- (2019) Xiaoming Jia et al. CIRCULATION
- A Feasible, Simple, Cost-saving Program to End Cardiovascular Disease in the United States
- (2019) David S. Schade et al. AMERICAN JOURNAL OF MEDICINE
- The cost-effectiveness of omega-3 polyunsaturated fatty acids – The Australian healthcare perspective
- (2019) Lan Gao et al. European Journal of Internal Medicine
- The Economic Burden of Hypertriglyceridemia Among US Adults With Diabetes or Atherosclerotic Cardiovascular Disease on Statin Therapy*
- (2019) Brian C. Case et al. Journal of Clinical Lipidology
- Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
- (2019) Ann C. Skulas-Ray et al. CIRCULATION
- Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients
- (2019) Peter P. Toth et al. MAYO CLINIC PROCEEDINGS
- National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk
- (2019) Carl E. Orringer et al. Journal of Clinical Lipidology
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value
- (2018) Steven D. Pearson VALUE IN HEALTH
- A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses
- (2018) Joseph Levy et al. VALUE IN HEALTH
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Absolute risks rather than incidence rates should be used to estimate the number needed to treat from time-to-event data
- (2013) Ralf Bender et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Number needed to treat is incorrect without proper time-related considerations
- (2011) Daniel Suissa et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More